|Description||PRD-125 is a potent SOAT2 inhibitor derived from pyripyropene A. Study shows that PRD-125 can suppress cholesterol diet-induced fatty liver progression in dose dependent manner and reduce the risk of atherosis in rabbit model.|
|Brife Description||SOAT2 inhibitor|
|Synonyms||PRD-125; PRD 125; PRD125|
|Application||the potential treatment of atherosis|
|Current Developer||Kitasato Institute|
BAY 41-4109 is a novel drug inhibiting hepatitis B virus capsid formation and replication.
Chlorpropamide is a drug in the sulfonylurea class used to treat type 2 diabetes mellitus. It is a long-acting 1st generation sulfonylurea.
Amedalin Hydrochloride, with antidepressant effect, is a selective norepinephrine reuptake inhibitor.
PPNDS is a potent and selective P2X1 receptor antagonist (pKB = 7.43 in rat vas deferens). PNDS is approximately 50-fold less selective for P2Y1R and does not i...
TMPA is an antagonist of nuclear receptor Nur77 (Kd = 1.45 ± 0.35 μM) and LKB1 interaction.
O-2093 is an inhibitor of anandamide uptake with IC50 of 17.3 μM. It shows little or no activity at CB1, CB2, TRPV1 and FAAH. Its intravenous administration inh...
Apocynin, also known as acetovanillone, is a natural organic compound structurally related to vanillin. It has been isolated from a variety of plant sources and...
D-AP4 has been found to be an excitatory amino acid receptor antagonist as well as an agonist at the quisqualate-sensitized AP6 site.